Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
Open Access
- 1 December 2015
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 96 (3) , 498-506
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (2009 × 23L78_005)
- Associazione Italiana per la Ricerca sul Cancro (MFAG 14282)
This publication has 27 references indexed in Scilit:
- Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer PatientsEuropean Urology, 2015
- P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective studyEuropean Urology Supplements, 2014
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneEuropean Journal of Cancer, 2014
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatmentCancer, 2013
- Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive FactorsUrology, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009